Madrigal (MDGL) Up 21.9% Since Last Earnings Report: Can It Continue?
Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock?
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Jefferies London Healthcare Conference 2025 Transcript
Madrigal Pharmaceuticals, Inc. ( MDGL ) Jefferies London Healthcare Conference 2025 November 20, 2025 3:30 AM EST Company Participants William Sibold - CEO, President & Director Mardi Dier - Executive VP & CFO David Soergel - Executive VP & Chief Medical Officer Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Presentation Akash Tewari Jefferies LLC, Research Division Good morning, everyone. We've made it to our last day of our London Healthcare Conference.
Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up
MDGL's wider Q3 loss fails to deter investors, as soaring Rezdiffra sales drive revenues past estimates and lift the stock.
Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2025 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. ( MDGL ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants Tina Ventura - Chief Investor Relations Officer William Sibold - CEO, President & Director David Soergel - Executive VP & Chief Medical Officer Mardi Dier - Executive VP & CFO Conference Call Participants Yasmeen Rahimi - Piper Sandler & Co., Research Division Jay Olson - Oppenheimer & Co. Inc., Research Division Michael DiFiore - Evercore ISI Institutional Equities, Research Division Akash Tewari - Jefferies LLC, Research Division Thomas Smith - Leerink Partners LLC, Research Division Andrea Tan - Goldman Sachs Group, Inc., Research Division Ritu Baral - TD Cowen, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Srikripa Devarakonda - Truist Securities, Inc., Research Division Kaveri Pohlman - Clear Street LLC Presentation Operator Good morning, and thank you for standing by. Welcome to the Madrigal Pharmaceuticals Third Quarter 2025 Earnings Conference Call.
Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates
Madrigal (MDGL) came out with a quarterly loss of $5.08 per share versus the Zacks Consensus Estimate of a loss of $1.98. This compares to a loss of $4.92 per share a year ago.
Madrigal (MDGL) Expected to Beat Earnings Estimates: Should You Buy?
Madrigal (MDGL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Madrigal Pharmaceuticals: Rezdiffra Commercialization Bodes Well For Continued Growth
Madrigal Pharmaceuticals is reiterated as a Strong Buy, driven by Rezdiffra's rapid US launch and recent European approval. Q2 2025 saw Rezdiffra sales reach $213M and >23,000 patients, with Q3 expectations of $245M and continued explosive growth. MDGL's strategic GLP-1 partnership and extended patent exclusivity through 2045 position it for long-term growth in the MASH market.
Madrigal Pharma CEO talks competition in the liver disease treatment space
Bill Sibold, Madrigal Pharma CEO, joins 'Fast Money' to talk how Rezdiffra stacks up to competitors in the MASH treatment space, sales growth for the drug over the last year, and more.
Madrigal Pharmaceuticals: Rezdiffra's US And EU Rollout Remains Promising
MDGL's Rezdiffra is its main value driver. This is the first FDA-approved MASH F2–F3 therapy. So far, Rezdiffra shows a rapid U.S. uptake and market penetration. Management projects over 23,000 patients by Q2 2025. The EU also granted Rezdiffra a conditional authorization. It will soon launch in Germany, and it has a sizeable initial European target of diagnosed F2–F3 patients.
Madrigal Pharmaceuticals, Inc. (MDGL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:45 AM EDT Company Participants William Sibold - CEO, President & Director David Soergel - Executive VP & Chief Medical Officer Mardi Dier - Executive VP & CFO Presentation Unknown Analyst Good morning, everyone. Very excited to be kicking off the Morgan Stanley Healthcare Conference with the Madrigal team this morning.
Madrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU
MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.
Madrigal Pharmaceuticals: A High-Paced Launch That Could Grow Further
Rezdiffra's Q2 '25 net sales surged 55% to $212.8M, beating expectations and highlighting strong commercial momentum for Madrigal Pharmaceuticals, Inc. Despite robust revenue growth, Madrigal Pharmaceuticals still reported a net loss of $42.3M, though profitability may be near. Approval of Rezdiffra in the EU could come in August 2025, with a launch by MDGL in Germany in H2 '25 possible.
